A recent posting by Value Market Research highlighted BBCR Consulting among others relating to the global oncology Biomarker market and its projected broad growth.

BBCR=Simplifying Clinical Research

Interest is increasing rapidly in using surrogate markers as primary measures of the effectiveness of investigational drugs in definitive drug trials. The primary difference between a biomarker and a surrogate marker is that a biomarker is a “candidate” surrogate marker. In contrast, a surrogate marker is a test used and taken to measure the effects of a specific treatment.

In orphan diseases and precision medicine, developing a biomarker plan during translation into early clinical development moves treatment to market faster, still meeting the FDA’s expectations.

As Nisha Naroliya from Value Market Research shared, increased funding in the areas of cancer research are causing a growth surge in Biomarker research (See Link). To learn more how BBCR Consulting can help with your Biomarker Strategy and Validation or Qualification needs, we invite you to reach out to us here.

Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.

"*" indicates required fields

NAME:*

EMAIL:*

PHONE NUMBER:

COMMENTS:*

CAPTCHA

Comments

This field is for validation purposes and should be left unchanged.